The identification of RSPO3 overexpression in STS patients’ tissue samples by our group could be used as preliminary data to support further preclinical studies in order to evaluate the effect of this monoclonal antibody in STS, whether administrated alone or in combination with DXR. The gene discussed is RSPO3; the disease is telomere syndrome.